Implantation tests have been conducted in a variety of in vivo models whereby particulate Bioglass® (sold under the brand names of PerioGlas® and NovaBone®) has been placed into a defect site and the presence of the graft material has been evaluated for up to 12 months. The reactions responsible for the initial particle surface dissolution and the formation of bone on the particle surfaces continue as long as the particle is present. The particles are gradually consumed as they are constantly re-exposed during bone remodeling, the rate of absorption being partially dependant on graft site and model. In one study, histologic evaluations indicated an average of 35% of the total defect cross sectional area as filled with graft material immediately after placement. By three months, this content had decreased by 80% down to 7%. At six months, the total graft content had decreased to 5%. In a similar study with a maximum duration of one year, the graft content decreased with time, having content values of 17%, 2% and <0.5% at periods of six weeks, six months, and twelve months respectively.

In the above studies, histologic observations have demonstrated the fate of the individual particles, with their gradual reduction in overall size and physical breakdown while encapsulated in bone. These same observations have also been seen in limited human histology cases where biopsies of graft sites have been taken.

More information can be found in the white paper below:

Resorption - White Paper

  Resorption

The purpose of bone grafting is regeneration and not replacement. Resorption plays a very critical role in the regeneration and remodeling of graft material into bone.

Bioactive Glass has been used as a bone graft material for over a decade. It has been used in over 850,000 medical/dental applications. Bioactive glass has a long standing proven record of safety and efficacy.